New immune therapy takes on tough lymphoma
NCT ID NCT06486051
First seen Mar 11, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This phase 2 trial tests a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has returned or not responded to standard treatment. About 60 participants will receive the therapy after a short course of chemotherapy. Researchers will track how many achieve complete remission and how many experience brain-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Christchurch Hospital
RECRUITINGChristchurch, Christchurch Central, 8011, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wellington Hospital
RECRUITINGNewtown, Wellington Region, 6021, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WZTL-002 CAR T-cells (a type of immune cell therapy that targets CD19 on cancer cells)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat large B-cell lymphoma, potentially leading to complete remission.
What could go wrong
This is a mid-stage trial with only 60 participants, so results may not apply to everyone. There are known risks of serious side effects like neurotoxicity and cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.